They're weighing the impact on their future workforce pipeline (and probably hoping this this only represents a ~4-8 year hiccup) against whatever other benefits they can get from cozying up with the administration (whacky regulation land).
And who knows, with the right wacky regulatory scheme enacted, the workforce impact will be mitigated away. Probably also banking on the size and power of the American domestic economy to still allow them to siphon talent from across the western world to help make up some short falls.
I was just talking to my buddy who works in big pharma and internally it sounds like they have zero concerns about the current administration impacting them.
Actually the opposite, apparently Trump rolled back the Medicare drug cost caps so they're expecting profits to go up.
They are currently on their way to Mar a Lago to ask Trump to roll back the drug price negotiation provisions that were instated by the Inflation Reduction Act
If they are protected from competition they will end up like the US auto industry in the 1970's. They can try and do generics but Teva, Ranbaxy and Ratiopharm will eat them once patent protection runs out.
